Differential Diagnosis of Diabetic Ketoacidosis: A Comprehensive Guide

Diabetic ketoacidosis (DKA) is a severe and potentially life-threatening complication of diabetes mellitus, primarily characterized by hyperglycemia, metabolic acidosis, and ketonemia. While DKA is often straightforward to diagnose in patients with known diabetes presenting with classic symptoms, its varied clinical presentations can sometimes overlap with other medical conditions. This necessitates a robust understanding of the differential diagnosis of diabetic ketoacidosis to ensure accurate diagnosis and timely, appropriate management. Missing the correct diagnosis can lead to delayed treatment, exacerbation of the actual underlying condition, and potentially adverse patient outcomes. This article serves as a comprehensive guide for healthcare professionals to navigate the differential diagnosis of DKA, enhancing diagnostic accuracy and improving patient care.

Understanding Diabetic Ketoacidosis (DKA)

Diabetic ketoacidosis arises from a critical deficiency of insulin coupled with an excess of counter-regulatory hormones such as glucagon, catecholamines, cortisol, and growth hormone. This hormonal imbalance leads to a cascade of metabolic derangements. The lack of insulin impairs glucose uptake by cells, resulting in hyperglycemia. Simultaneously, the hormonal milieu promotes gluconeogenesis and glycogenolysis, further exacerbating elevated blood glucose levels. In the absence of sufficient glucose utilization, the body shifts to fatty acid metabolism for energy. This process, known as ketogenesis, leads to the overproduction of ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone) in the liver.

The accumulation of these acidic ketone bodies overwhelms the body’s buffering capacity, causing metabolic acidosis. Hyperglycemia also induces osmotic diuresis, leading to significant fluid and electrolyte losses, including sodium, potassium, phosphate, and magnesium. This dehydration and electrolyte imbalance contribute significantly to the severity of DKA.

Classic symptoms of DKA include polyuria, polydipsia, polyphagia, and weight loss, stemming from hyperglycemia and osmotic diuresis. As the condition progresses, patients may develop nausea, vomiting, abdominal pain, and the characteristic Kussmaul breathing – deep, labored respirations aimed at compensating for metabolic acidosis by expelling carbon dioxide. A fruity odor on the breath, due to exhaled acetone, may also be noticeable. In severe cases, altered mental status, ranging from drowsiness to coma, can occur.

The diagnostic criteria for DKA typically include:

• Hyperglycemia: Blood glucose levels generally above 250 mg/dL (13.9 mmol/L), although euglycemic DKA can occur, particularly in patients taking SGLT2 inhibitors.
• Metabolic Acidosis: Arterial pH < 7.3 or serum bicarbonate < 15 mEq/L.
• Ketonemia/Ketonuria: Presence of ketones in serum or urine.
• Elevated Anion Gap: Anion gap > 12 mEq/L, indicating the presence of unmeasured anions like ketone bodies.

While these criteria are helpful, relying solely on them can be misleading, especially when considering the differential diagnoses.

The Critical Importance of Differential Diagnosis in DKA

Accurate differential diagnosis in suspected DKA cases is paramount for several reasons:

• Preventing Misdiagnosis: Conditions that mimic DKA can present with similar symptoms, potentially leading to a misdiagnosis of DKA when another pathology is actually responsible.
• Ensuring Appropriate Treatment: Treating a mimicking condition as DKA will not address the true underlying problem and may even be harmful. Conversely, delaying or forgoing DKA treatment when it is genuinely present can have dire consequences.
• Improving Patient Outcomes: Prompt and accurate diagnosis, followed by targeted treatment, is crucial for optimizing patient outcomes and reducing morbidity and mortality associated with both DKA and its mimicking conditions.
• Identifying Underlying Etiologies: Differential diagnosis often helps in uncovering the root cause of the patient’s presentation, which may not always be diabetes-related. For example, toxic ingestions or certain metabolic disorders can mimic DKA.

The overlapping symptoms between DKA and other conditions, particularly in patients without a known history of diabetes or in atypical presentations of DKA (like euglycemic DKA), underscore the importance of a systematic approach to differential diagnosis. Failing to consider alternative diagnoses can result in delayed or inappropriate management, potentially worsening the patient’s condition.

Key Conditions in the Differential Diagnosis of DKA

Several conditions can mimic DKA, necessitating careful clinical evaluation and targeted investigations to differentiate them. These key conditions include:

1. Hyperosmolar Hyperglycemic State (HHS)

Hyperosmolar Hyperglycemic State (HHS), previously known as hyperosmolar nonketotic coma (HONK), represents another hyperglycemic crisis in diabetes. While both DKA and HHS are serious complications of diabetes, they differ in their primary pathophysiological characteristics and typical patient profiles.

Distinguishing Features from DKA:

• Ketone Production and Acidosis: The most crucial differentiating factor is the degree of ketosis and acidosis. In HHS, while there may be mild ketosis, it is significantly less pronounced than in DKA. Acidosis is typically absent or mild in HHS. This is primarily because, in HHS, there is usually enough insulin present to suppress lipolysis and ketogenesis, although it is insufficient to facilitate glucose uptake effectively.
• Serum Osmolality: HHS is characterized by significantly higher serum osmolality (typically > 320 mOsm/kg) due to more profound dehydration and hyperglycemia. In DKA, while osmolality is elevated, it is generally lower than in HHS.
• Blood Glucose Levels: Hyperglycemia is typically more severe in HHS, with blood glucose levels often exceeding 600 mg/dL (33.3 mmol/L) and frequently surpassing 1000 mg/dL. While hyperglycemia is also a hallmark of DKA, glucose levels are usually in the range of 250-600 mg/dL.
• Typical Patient Profile: HHS is more commonly seen in patients with type 2 diabetes, particularly older adults with comorbidities. DKA, while also occurring in type 2 diabetes, is more frequently associated with type 1 diabetes.

Clinical Presentation Differences:

• Dehydration: Dehydration is usually more severe in HHS due to the extreme hyperglycemia and resulting osmotic diuresis. Patients with HHS often present with profound dehydration.
• Neurological Symptoms: Neurological manifestations are more prominent and severe in HHS due to the hyperosmolarity. These can range from lethargy, confusion, and seizures to coma. In DKA, altered mental status is also common but may be more directly related to acidosis and cerebral edema, especially in children.
• Abdominal Pain: Abdominal pain, a common symptom in DKA, is less frequently observed in HHS.

Differentiating Lab Tests:

• Serum Ketones and Arterial Blood Gas (ABG): Essential for differentiating. DKA shows significant ketonemia and metabolic acidosis (low pH, low bicarbonate). HHS shows minimal ketones and near-normal pH and bicarbonate.
• Serum Osmolality: Calculate serum osmolality: 2[Na+] + Glucose/18 + BUN/2.8 (using mg/dL for glucose and BUN). Elevated osmolality (>320 mOsm/kg) strongly suggests HHS.

Clinical Context: Consider the patient’s diabetes history, age, and presenting symptoms to differentiate between DKA and HHS. While both require aggressive fluid resuscitation and insulin therapy, the rate and type of fluid replacement, as well as insulin administration, might be adjusted based on the specific diagnosis.

2. Alcoholic Ketoacidosis (AKA)

Alcoholic ketoacidosis (AKA) is a metabolic complication of chronic alcohol abuse, characterized by metabolic acidosis and ketosis, often occurring after a period of heavy drinking followed by starvation or reduced food intake.

Differentiating Features from DKA:

• History of Alcohol Abuse: A strong history of chronic alcohol use or recent heavy drinking is a key indicator of AKA. This history is typically absent in DKA patients, unless alcohol abuse is a co-precipitating factor for DKA.
• Blood Glucose Levels: Unlike DKA, blood glucose levels in AKA are often normal or even low (hypoglycemic ketoacidosis). Hyperglycemia can occur but is less typical and less severe than in DKA.
• Clinical Context: AKA typically develops in individuals with a history of alcohol dependence who have experienced recent binge drinking followed by decreased oral intake, often due to nausea, vomiting, or abdominal pain associated with alcohol withdrawal or gastritis.

Clinical Presentation Differences:

• Nausea, Vomiting, Abdominal Pain: These symptoms are prominent in both AKA and DKA, but in AKA, they are often directly related to alcohol withdrawal, gastritis, or pancreatitis induced by alcohol.
• Signs of Alcohol Withdrawal: Tremors, anxiety, agitation, and in severe cases, hallucinations or seizures, may be present in AKA due to alcohol withdrawal. These are not features of DKA unless alcohol withdrawal is a co-occurring condition.
• Lack of Polyuria/Polydipsia: Due to often normal or low glucose levels, polyuria and polydipsia, classic symptoms of DKA, are less prominent in AKA.

Differentiating Lab Tests:

• Blood Glucose: Crucial differentiator. Normal or low glucose levels are characteristic of AKA, while DKA typically presents with hyperglycemia.
• Blood Alcohol Level: May be helpful, although it can be negative if the patient has metabolized all the alcohol. However, a history of recent alcohol intake is more critical.
• Ketone Bodies: Both AKA and DKA show ketonemia and ketonuria. However, the ratio of beta-hydroxybutyrate to acetoacetate may be higher in AKA.
• Lactate Levels: Lactate levels may be elevated in AKA, particularly if there is associated dehydration, vomiting, or alcohol withdrawal seizures. However, significantly elevated lactate suggests lactic acidosis as a primary diagnosis or a co-existing condition.

Clinical Management: While both AKA and DKA require fluid resuscitation and electrolyte management, insulin therapy is generally less critical in AKA and may even be contraindicated if hypoglycemia is present. The primary treatment for AKA involves intravenous fluids (often with dextrose to address hypoglycemia and provide substrate for metabolism), electrolyte repletion (especially potassium, magnesium, and phosphate), and thiamine to prevent Wernicke-Korsakoff syndrome in chronic alcohol users. Addressing alcohol withdrawal symptoms with benzodiazepines may also be necessary.

3. Starvation Ketosis

Starvation ketosis is a physiological state of ketosis that develops during prolonged fasting or very low-carbohydrate diets. It’s a milder form of ketosis compared to DKA and AKA.

Differentiating Features from DKA:

• Degree of Ketosis and Acidosis: Ketosis in starvation is less severe than in DKA. While ketone bodies are elevated, the degree of metabolic acidosis is minimal or absent. The body’s buffering systems can typically compensate for the mild increase in ketones.
• Blood Glucose Levels: Blood glucose levels are typically low or normal in starvation ketosis, unlike the hyperglycemia seen in DKA.
• Clinical History: A history of prolonged fasting, calorie restriction, or a ketogenic diet is crucial in identifying starvation ketosis. DKA is usually triggered by insulin deficiency or increased insulin requirements due to illness, not simply dietary restriction.

Clinical Presentation Differences:

• Symptoms: Symptoms are generally mild in starvation ketosis and may include fatigue, mild lightheadedness, and a fruity odor to the breath. The severe symptoms of DKA, such as marked dehydration, vomiting, abdominal pain, and altered mental status, are absent in uncomplicated starvation ketosis.
• Absence of Severe Illness: Starvation ketosis occurs in the absence of acute illness, infection, or other stressors that precipitate DKA.

Differentiating Lab Tests:

• Blood Glucose: Normal or low in starvation ketosis, elevated in DKA.
• Arterial Blood Gas (ABG): pH and bicarbonate are typically normal in starvation ketosis or show only very mild changes. DKA is characterized by significant metabolic acidosis.
• Serum Ketones: Elevated in both conditions but generally lower in starvation ketosis. Quantitative ketone measurements might help, but clinical context is more important.

Clinical Management: Starvation ketosis is generally benign and resolves with carbohydrate refeeding. Treatment for DKA (insulin, aggressive fluid and electrolyte replacement) is not needed and would be inappropriate for starvation ketosis. The primary management involves nutritional support and addressing any underlying reasons for prolonged fasting, if applicable.

4. Lactic Acidosis

Lactic acidosis is a metabolic disorder characterized by the buildup of lactic acid in the body, leading to metabolic acidosis. It’s a broad category with various underlying causes, and certain forms can mimic DKA in some aspects.

Differentiating Features from DKA:

• Primary Acidosis Mechanism: In lactic acidosis, the acidosis is due to elevated lactic acid, not ketone bodies as in DKA. While DKA can sometimes have a component of lactic acidosis due to hypoperfusion, in primary lactic acidosis, lactate is the dominant acid.
• Blood Glucose Levels: Blood glucose can be variable in lactic acidosis depending on the underlying cause. It can be normal, high (e.g., in sepsis or stress hyperglycemia), or low (e.g., in metformin-associated lactic acidosis). It is not consistently hyperglycemic as in classic DKA.
• Serum Ketones: Serum ketones are typically absent or minimally elevated in lactic acidosis. Significant ketonemia is not a feature of primary lactic acidosis.

Clinical Presentation Differences:

• Clinical Context: Lactic acidosis is usually associated with conditions causing tissue hypoperfusion or impaired oxygen delivery (sepsis, shock, severe heart failure, ischemia), certain medications (metformin, nucleoside reverse transcriptase inhibitors), or metabolic disorders. DKA is primarily linked to insulin deficiency in diabetes.
• Signs of Hypoperfusion: Patients with lactic acidosis may exhibit signs of shock or hypoperfusion, such as hypotension, poor peripheral perfusion, and altered mental status due to hypoxemia or systemic illness. These signs might be less prominent in early or mild DKA, unless severe dehydration and shock develop as complications.
• Absence of Classic DKA Symptoms: While altered mental status and tachypnea can be present in both, the classic symptoms of DKA like polyuria, polydipsia, and fruity breath may be absent or less pronounced in lactic acidosis unless diabetes and DKA are also present.

Differentiating Lab Tests:

• Lactate Level: The key differentiating test. Markedly elevated lactate levels (>4-5 mmol/L) are diagnostic of lactic acidosis. Lactate is typically normal or only mildly elevated in uncomplicated DKA.
• Serum Ketones: Generally low or absent in lactic acidosis. DKA shows significant ketonemia.
• Arterial Blood Gas (ABG): Both conditions present with metabolic acidosis. However, in lactic acidosis, the anion gap acidosis is due to lactate, while in DKA, it’s primarily due to ketone bodies.
• Blood Glucose: Variable in lactic acidosis, consistently elevated in classic DKA.

Clinical Management: Management of lactic acidosis is directed at treating the underlying cause. This may involve sepsis management, improving tissue perfusion, discontinuing offending medications, or addressing metabolic disorders. Insulin therapy is not a primary treatment for lactic acidosis unless co-existing DKA is present. Bicarbonate therapy may be considered in severe lactic acidosis (pH < 7.1), although its benefit is debated.

Subtypes of Lactic Acidosis and Mimicry:

• Metformin-Associated Lactic Acidosis (MALA): Can be particularly challenging to differentiate as metformin is used in type 2 diabetes, and patients might present with hyperglycemia or even euglycemia. MALA should be considered in diabetic patients on metformin presenting with unexplained metabolic acidosis, even without marked hyperglycemia or ketosis.
• Sepsis-Induced Lactic Acidosis: Sepsis can also trigger DKA in diabetic patients. In these cases, both ketosis and lactic acidosis may be present. However, in sepsis-induced lactic acidosis without DKA, lactate elevation is the primary feature, and ketosis is less prominent.

5. Sepsis

Sepsis, the body’s overwhelming response to infection, can present with metabolic disturbances that can mimic or overlap with DKA. Furthermore, infection is a well-known precipitating factor for DKA.

Differentiating Features from DKA (when sepsis is not triggering DKA, but mimicking it):

• Primary Underlying Pathology: Sepsis is primarily an infectious process, while DKA is a metabolic disorder arising from insulin deficiency. However, the two can coexist, with sepsis triggering DKA.
• Ketogenesis vs. Systemic Inflammation: While both involve metabolic derangements, DKA’s acidosis is primarily from ketogenesis, whereas sepsis involves a complex interplay of inflammatory mediators, metabolic changes (including lactic acidosis, but not primarily ketosis), and organ dysfunction.
• Blood Glucose Variability in Sepsis: Sepsis can cause both hyperglycemia (stress hyperglycemia) and hypoglycemia (especially in severe sepsis or septic shock). While hyperglycemia can be present in sepsis, it’s not necessarily accompanied by significant ketosis as in DKA, unless the patient also has diabetes and develops DKA secondary to the infection.

Clinical Presentation Differences:

• Signs of Infection: Fever, chills, localized signs of infection (pneumonia, UTI, cellulitis), elevated white blood cell count are prominent in sepsis. These may or may not be present in DKA if infection is not the trigger.
• Hypotension and Shock: Hypotension and shock are more common and earlier features of severe sepsis than in uncomplicated DKA, although DKA can progress to hypovolemic shock due to dehydration.
• Organ Dysfunction: Sepsis is defined by organ dysfunction. Signs of respiratory distress (ARDS), acute kidney injury, liver dysfunction, and coagulopathy are more suggestive of sepsis than DKA alone.
• Less Prominent Polyuria/Polydipsia: Unless the patient also has diabetes and hyperglycemia, polyuria and polydipsia are not typical presenting symptoms of sepsis mimicking DKA.

Differentiating Lab Tests:

• White Blood Cell Count (WBC): Usually elevated in sepsis, may be elevated in DKA (stress leukocytosis), but very high WBC count with bandemia strongly suggests infection.
• Lactate Level: Elevated lactate is common in sepsis due to tissue hypoperfusion and metabolic stress. DKA typically does not present with significant lactic acidosis unless there is severe dehydration and shock.
• Blood Cultures and Infection Workup: Essential in suspected sepsis. Positive cultures or other evidence of infection (chest X-ray for pneumonia, urinalysis for UTI) point towards sepsis.
• Serum Ketones: Ketones are usually absent or minimally elevated in sepsis unless the patient also has DKA. Significant ketonemia strongly favors DKA.
• Procalcitonin and CRP: Inflammatory markers like procalcitonin and C-reactive protein (CRP) are typically elevated in sepsis, reflecting the inflammatory response to infection.

Clinical Management: Sepsis management prioritizes early antibiotic administration, source control of infection, hemodynamic support (fluid resuscitation, vasopressors), and organ support. Insulin therapy is not the primary treatment for sepsis mimicking DKA, although insulin may be used to manage stress hyperglycemia in septic patients. If DKA is also present due to sepsis as a trigger, then DKA-specific treatment (insulin, fluids, electrolytes) is also essential.

6. Toxicologic Exposures (Ethylene Glycol, Methanol, Paraldehyde, Salicylate)

Ingestion of certain toxins can lead to metabolic acidosis and clinical presentations that can mimic DKA. These toxic ingestions are critical to consider in the differential diagnosis, especially in patients presenting with unexplained metabolic acidosis.

Specific Toxins and Mechanisms Mimicking DKA:

• Ethylene Glycol (Antifreeze): Metabolized into toxic metabolites, including glycolic acid and oxalic acid, causing severe anion gap metabolic acidosis, acute kidney injury (due to oxalate crystal deposition in kidneys), and neurological effects. It does not directly cause ketosis, but the overall clinical picture of severe acidosis and altered mental status can be misleading.
• Methanol (Wood Alcohol): Metabolized to formaldehyde and formic acid, leading to severe anion gap metabolic acidosis, visual disturbances (optic neuritis), and neurological damage. Like ethylene glycol, it causes acidosis but not primarily ketosis.
• Paraldehyde (Historically used sedative): Metabolized to acetic acid, causing anion gap metabolic acidosis and a characteristic pungent odor on the breath that can be mistaken for acetone breath of DKA. It does not cause ketosis.
• Salicylates (Aspirin): In overdose, salicylates can cause a mixed acid-base disorder: initially respiratory alkalosis (due to stimulation of the respiratory center) followed by anion gap metabolic acidosis. Salicylates do not directly cause ketosis, but the overall presentation with acidosis and altered mental status can overlap with DKA.

Differentiating Features from DKA:

• History of Ingestion: Obtaining a history of possible toxin ingestion is crucial. This may be accidental (especially in children) or intentional (suicide attempt). However, patients may be unreliable historians, especially if altered mental status is present.
• Osmolar Gap: Ethylene glycol and methanol, being small molecules, increase the measured serum osmolality more than predicted by the usual formula (2[Na+] + Glucose/18 + BUN/2.8). An elevated osmolar gap (>10 mOsm/kg) is a strong clue to ethylene glycol or methanol poisoning. DKA typically does not cause a significant osmolar gap.
• Specific Toxic Effects: Visual disturbances (methanol), flank pain and hematuria (ethylene glycol due to oxalate nephropathy), and tinnitus (salicylates) are suggestive of specific toxic ingestions, not typically seen in DKA.

Differentiating Lab Tests:

• Osmolar Gap Calculation: Calculate and evaluate the osmolar gap.
• Anion Gap: All these toxic ingestions cause anion gap metabolic acidosis, similar to DKA.
• Serum or Urine Toxicology Screens: Specific assays for ethylene glycol, methanol, salicylate levels are essential to confirm the diagnosis. These tests are not needed in routine DKA diagnosis.
• Calcium Levels (Ethylene Glycol): Hypocalcemia can occur in ethylene glycol poisoning due to calcium oxalate precipitation.
• Arterial Blood Gas (ABG): Acidosis is present in both DKA and toxic ingestions. However, salicylate poisoning may initially present with respiratory alkalosis.
• Serum Ketones: Generally low or absent in toxic ingestions (except in rare cases where toxic ingestion co-occurs with diabetes and DKA). DKA shows significant ketonemia.

Clinical Management: Management of toxic ingestions is toxin-specific and often involves:

• Antidotes: Fomepizole or ethanol (for ethylene glycol and methanol), sodium bicarbonate (for salicylate poisoning), although no specific antidote for paraldehyde.
• Enhanced Elimination: Hemodialysis is often necessary to remove the toxin and its toxic metabolites, especially in severe ethylene glycol, methanol, or salicylate poisoning.
• Supportive Care: Similar to DKA, supportive care includes fluid resuscitation, electrolyte correction, and management of acidosis. However, insulin is not part of the treatment for these toxic ingestions unless co-existing DKA is present.

7. Diabetic Medication Overdose (Insulin/Sulfonylureas)

Overdosing on insulin or sulfonylureas, while primarily causing hypoglycemia, can paradoxically lead to rebound ketosis and metabolic acidosis in some situations, especially with long-acting insulin or sulfonylureas.

Differentiating Features from DKA (when presenting with ketoacidosis):

• Primary Effect is Hypoglycemia: The hallmark of insulin or sulfonylurea overdose is hypoglycemia. While rebound hyperglycemia can occur later, the initial presentation is usually low blood glucose. DKA, in contrast, begins with hyperglycemia.
• Clinical History of Medication Overdose: History of intentional or accidental overdose of insulin or sulfonylureas is crucial. This is typically absent in classic DKA (unless medication non-compliance leads to DKA, but not overdose).
• Context of Treatment: This scenario is more likely to occur in patients already being treated for diabetes with insulin or sulfonylureas, not in new-onset diabetes presenting with DKA.

Clinical Presentation Differences:

• Hypoglycemic Symptoms Initially: Symptoms of hypoglycemia (sweating, tremors, palpitations, anxiety, confusion, seizures) are usually the initial presentation. These are not the primary symptoms of DKA onset.
• Variable Blood Glucose: Blood glucose can fluctuate widely, initially low, then potentially rising due to counter-regulatory hormone response and rebound hyperglycemia. DKA is characterized by persistently high glucose.
• Less Severe Dehydration Initially: Dehydration may develop later due to vomiting or osmotic diuresis from rebound hyperglycemia, but is not as prominent initially as in DKA.

Differentiating Lab Tests:

• Blood Glucose Trend: Monitor blood glucose closely. Initial hypoglycemia followed by potential rebound hyperglycemia and ketosis is suggestive. DKA shows persistently high glucose.
• Insulin Levels (if available): Elevated serum insulin or C-peptide levels in the context of hypoglycemia would support insulin overdose.
• Sulfonylurea Levels (if available): Detecting sulfonylureas in serum would confirm sulfonylurea overdose.
• Serum Ketones and ABG: Ketonemia and metabolic acidosis may develop, especially with prolonged hypoglycemia and counter-regulatory hormone response. However, the degree of ketosis and acidosis is usually less severe than in classic DKA.

Clinical Management: Primary management is to correct hypoglycemia with intravenous glucose. For sulfonylurea overdose, octreotide (somatostatin analog) can inhibit insulin secretion. Monitoring for rebound hypoglycemia and hyperglycemia is crucial. Fluid and electrolyte replacement may be needed if significant dehydration develops. DKA-specific treatment (insulin drip) is generally not indicated unless there is persistent, severe hyperglycemia and ketosis despite glucose administration.

8. Uremia (Metabolic Acidosis of Renal Failure)

Uremia, the clinical syndrome of end-stage renal disease, is characterized by metabolic acidosis due to the kidney’s inability to excrete acid and regenerate bicarbonate. While it can cause anion gap metabolic acidosis, it is distinct from DKA.

Differentiating Features from DKA:

• Underlying Chronic Kidney Disease (CKD): Patients with uremic acidosis have a history of CKD, often with known elevated creatinine and reduced glomerular filtration rate (GFR). This history is not present in new-onset DKA and may or may not be present in established diabetes patients developing DKA.
• Mechanism of Acidosis: Uremic acidosis is due to impaired renal acid excretion and bicarbonate regeneration, not ketogenesis. While both cause anion gap acidosis, the underlying mechanism is different.
• Serum Ketones: Serum ketones are typically absent or minimally elevated in uremic acidosis. Significant ketonemia is not a feature of uremia.

Clinical Presentation Differences:

• Signs and Symptoms of CKD: Patients may have signs and symptoms of CKD, such as edema, hypertension, uremic symptoms (fatigue, anorexia, nausea, pruritus), and volume overload. These are not typical presenting features of DKA.
• Lack of Classic DKA Symptoms: Polyuria, polydipsia, polyphagia, and fruity breath are not characteristic of uremic acidosis unless the patient also has diabetes and DKA.

Differentiating Lab Tests:

• BUN and Creatinine: Markedly elevated BUN and creatinine are hallmarks of uremia. While BUN and creatinine can be elevated in DKA due to dehydration and pre-renal azotemia, they are usually not as dramatically elevated as in end-stage renal disease.
• Serum Bicarbonate and pH: Both uremia and DKA cause metabolic acidosis (low bicarbonate and pH).
• Serum Ketones: Generally low or absent in uremia. DKA shows significant ketonemia.
• Urine Ketones: Negative in uremia, positive in DKA.
• Renal Ultrasound/History: Evidence of chronic kidney disease on imaging or patient history supports uremia.

Clinical Management: Management of uremic acidosis focuses on treating the underlying renal failure. This may include:

• Sodium Bicarbonate: Oral or intravenous bicarbonate can be used to correct metabolic acidosis in CKD.
• Dialysis: Hemodialysis or peritoneal dialysis is often necessary in severe uremia to remove waste products, correct fluid overload, and manage acidosis.
• Dietary Management: Protein restriction and electrolyte management are part of long-term CKD care.

Insulin therapy is not indicated for uremic acidosis unless the patient also has diabetes and DKA. In fact, insulin requirements may be reduced in renal failure due to decreased insulin clearance.

9. Myocardial Infarction & Pancreatitis

While not directly mimicking the metabolic acidosis and ketosis of DKA, acute myocardial infarction (MI) and acute pancreatitis can present with abdominal pain, nausea, vomiting, and general malaise, symptoms that overlap with DKA, particularly atypical presentations of DKA where abdominal pain is prominent.

Differentiating Features from DKA:

• Primary Symptom Focus: MI is primarily a cardiac event, and pancreatitis is primarily an inflammatory condition of the pancreas. DKA is a metabolic derangement of diabetes. However, all three can cause abdominal pain.
• Ketosis and Acidosis (Absent in MI and Pancreatitis): Neither MI nor uncomplicated pancreatitis directly causes ketosis or significant metabolic acidosis. While pancreatitis can sometimes lead to mild metabolic acidosis, it is not primarily due to ketone bodies.
• Blood Glucose (Variable in MI and Pancreatitis): Blood glucose may be elevated in MI and pancreatitis due to stress hyperglycemia, but this hyperglycemia is not associated with significant ketosis as in DKA.

Clinical Presentation Differences:

• Chest Pain (MI): Typical chest pain radiating to the left arm, jaw, or back is suggestive of MI, although atypical presentations, especially in diabetics and elderly, may present with abdominal pain or nausea alone (“anginal equivalents”).
• Epigastric or Upper Abdominal Pain (Pancreatitis): Severe, persistent epigastric or upper abdominal pain radiating to the back is characteristic of pancreatitis. While abdominal pain can occur in DKA, it’s usually more generalized and less localized to the upper abdomen.
• Cardiac Risk Factors (MI): Presence of cardiac risk factors (hypertension, hyperlipidemia, smoking, family history of heart disease) increases suspicion for MI in a patient presenting with chest or abdominal pain.

Differentiating Lab Tests:

• Cardiac Enzymes (Troponin) (MI): Elevated troponin levels are diagnostic of myocardial infarction. Troponin is not elevated in uncomplicated DKA or pancreatitis.
• Lipase and Amylase (Pancreatitis): Markedly elevated serum lipase (more specific) and amylase levels are diagnostic of acute pancreatitis. These enzymes may be mildly elevated in DKA due to metabolic stress but not to the degree seen in pancreatitis.
• ECG (MI): ECG changes (ST-segment elevation, ST-segment depression, T-wave inversions) are typical in MI. ECG is usually normal in uncomplicated DKA and pancreatitis (though electrolyte imbalances in DKA can cause ECG changes).
• Serum Ketones and ABG: Serum ketones are typically absent or minimally elevated in MI and pancreatitis (unless the patient also has diabetes and DKA). Arterial blood gas in uncomplicated MI and pancreatitis is usually normal or shows respiratory alkalosis due to pain and anxiety, not metabolic acidosis.

Imaging Studies:

• ECG (MI): First-line for suspected MI.
• Chest X-ray (Both): May show pulmonary edema in MI or complications of pancreatitis (pleural effusions, atelectasis).
• CT Scan of Abdomen (Pancreatitis): Abdominal CT scan is the imaging modality of choice to diagnose pancreatitis and assess its severity.

Clinical Management: Management is directed at the primary condition:

• MI: Immediate management of MI includes oxygen, aspirin, nitroglycerin, morphine, beta-blockers, anticoagulants, and reperfusion therapy (PCI or thrombolytics).
• Pancreatitis: Pancreatitis management is primarily supportive: intravenous fluids, pain control, nutritional support, and management of complications.

Insulin therapy is not indicated for MI or pancreatitis unless the patient also has diabetes and co-existing DKA or requires insulin for stress hyperglycemia management.

Diagnostic Approach to Differential Diagnosis

Navigating the differential diagnosis of DKA requires a systematic approach, incorporating history, physical examination, and targeted laboratory and imaging investigations.

1. Detailed History Taking:

• Diabetes History: Known diabetes diagnosis (type 1 or type 2), previous episodes of DKA, usual diabetes management, medication compliance, recent changes in medication or insulin regimen.
• Alcohol History: History of chronic alcohol abuse, recent alcohol intake, last drink, symptoms of alcohol withdrawal.
• Medication History: Current medications, including over-the-counter drugs, supplements, and SGLT2 inhibitors (which can predispose to euglycemic DKA). Any recent medication changes or overdoses.
• Toxic Exposure History: Possible ingestion of toxins (antifreeze, methanol, salicylates), especially in patients with altered mental status or unexplained acidosis.
• Infection History: Recent or current infections (fever, cough, urinary symptoms), potential sources of sepsis.
• Dietary History: Prolonged fasting, very low-carbohydrate diet (ketogenic diet), history of starvation or malnutrition (relevant to starvation ketosis).
• Renal History: History of chronic kidney disease, dialysis, recent changes in renal function.
• Cardiac History: History of coronary artery disease, risk factors for MI, symptoms of chest pain or anginal equivalents.
• Gastrointestinal History: History of pancreatitis, biliary disease, symptoms of abdominal pain, nausea, vomiting.

2. Thorough Physical Examination:

• Vital Signs: Assess for tachycardia, tachypnea (Kussmaul breathing), hypotension, fever or hypothermia (sepsis), respiratory rate and pattern.
• Hydration Status: Evaluate for dehydration (dry mucous membranes, poor skin turgor, tachycardia, hypotension).
• Neurological Examination: Assess mental status (alertness, orientation, confusion, lethargy, coma), focal neurological deficits (consider cerebral edema in DKA, toxic exposures).
• Breath Odor: Note fruity odor (acetone breath in DKA, starvation ketosis), pungent odor (paraldehyde poisoning).
• Abdominal Examination: Assess for abdominal tenderness, guarding, rebound tenderness (peritonitis, pancreatitis, DKA-related abdominal pain).
• Signs of Alcohol Withdrawal: Tremors, agitation, diaphoresis.
• Signs of Infection: Localized signs of infection, generalized sepsis signs.
• Signs of Uremia: Edema, uremic fetor (ammonia-like breath odor, less specific).
• Cardiac Exam: Listen for murmurs, gallops; assess for signs of heart failure.

3. Key Laboratory Investigations:

• Basic Metabolic Panel (BMP):
  • Blood Glucose: Essential to differentiate hyperglycemia (DKA, HHS, stress hyperglycemia) from normal or low glucose (AKA, starvation ketosis, some lactic acidosis, toxic ingestions, medication overdose).
  • Electrolytes: Sodium, potassium, chloride, bicarbonate – assess for anion gap metabolic acidosis.
  • BUN and Creatinine: Assess renal function, elevated in uremia, may be elevated in dehydrated DKA/HHS.
• Arterial Blood Gas (ABG) or Venous Blood Gas (VBG): Measure pH, pCO2, bicarbonate – confirm metabolic acidosis, assess severity.
• Serum Ketones: Quantitative beta-hydroxybutyrate measurement is preferred over urine ketones or nitroprusside tests (more sensitive and specific for ketosis). Essential for diagnosing DKA and differentiating from lactic acidosis, uremia, toxic ingestions.
• Lactate Level: Measure serum lactate to rule out or confirm lactic acidosis as a primary or co-existing condition.
• Osmolality (Calculated and Measured): Calculate osmolar gap to screen for ethylene glycol and methanol poisoning.
• Urinalysis: Urine ketones (qualitative, less reliable than serum ketones), urine glucose, urine electrolytes (if needed).
• Complete Blood Count (CBC): WBC count – elevated in sepsis, stress leukocytosis in DKA.
• Cardiac Enzymes (Troponin): Rule out myocardial infarction if chest pain or anginal equivalents are present.
• Lipase and Amylase: Rule out acute pancreatitis if abdominal pain is prominent.
• Liver Function Tests (LFTs): Assess liver function, may be abnormal in sepsis, alcoholic liver disease.
• Toxicology Screens: If toxic ingestion is suspected (ethylene glycol, methanol, salicylates, paraldehyde), order specific serum or urine toxicology tests.
• Blood Cultures: If sepsis is suspected.
• Blood Alcohol Level: If alcoholic ketoacidosis is suspected.

4. Imaging Studies (Selective Use):

• ECG: For chest pain or suspected MI.
• Chest X-ray: Rule out pneumonia (infection trigger for DKA or sepsis), assess for pulmonary edema (MI, severe fluid overload).
• Abdominal CT Scan: If pancreatitis is suspected, or to evaluate for other abdominal pathology if abdominal pain is severe or unexplained.
• Head CT or MRI: If altered mental status is severe or focal neurological deficits are present (rule out cerebral edema in DKA, toxic encephalopathy, stroke).

5. Clinical Algorithms and Decision-Making Frameworks:

• Utilize diagnostic algorithms that incorporate clinical features, laboratory findings, and risk factors to systematically narrow down the differential diagnosis.
• Consider the pre-test probability of each condition based on the patient’s clinical context.
• Employ a stepwise approach, starting with basic investigations (BMP, ABG, ketones, lactate) and then proceeding to more specific tests as needed based on clinical clues.
• Re-evaluate the diagnosis if the clinical picture evolves or if initial treatment is not effective.

Management Implications Based on Differential Diagnosis

The differential diagnosis significantly impacts the management approach. Misdiagnosing a condition mimicking DKA as DKA itself can lead to inappropriate treatment and potentially harmful consequences. Conversely, missing DKA when it is present can be equally dangerous.

• DKA Treatment: If DKA is confirmed, the management priorities are:

  • Fluid Resuscitation: Aggressive intravenous hydration to correct dehydration.
  • Insulin Therapy: Intravenous insulin infusion to correct hyperglycemia and suppress ketogenesis.
  • Electrolyte Replacement: Potassium, magnesium, phosphate repletion as needed.
  • Identify and Treat Precipitating Factors: Infection, medication non-compliance, etc.

• HHS Treatment: Similar to DKA, HHS management includes:

  • Aggressive Fluid Resuscitation: Often even more crucial than in DKA due to more severe dehydration.
  • Insulin Therapy: Lower doses of insulin may be needed compared to DKA due to less severe acidosis.
  • Electrolyte Management: Similar to DKA.
  • Address Underlying Cause.

• AKA Treatment:

  • Intravenous Fluids: Often with dextrose to address hypoglycemia and provide substrate.
  • Electrolyte Repletion: Potassium, magnesium, phosphate, thiamine.
  • Benzodiazepines: For alcohol withdrawal management if needed.
  • Insulin: Generally not primary treatment, may be needed if hyperglycemia is significant, but caution against hypoglycemia.

• Starvation Ketosis Treatment:

  • Carbohydrate Refeeding: Primary treatment is nutritional support with carbohydrates.
  • No Insulin Needed: Insulin is contraindicated.

• Lactic Acidosis Treatment:

  • Treat Underlying Cause: Sepsis management, improve perfusion, discontinue offending medications.
  • Supportive Care: Fluid resuscitation, oxygenation, hemodynamic support.
  • Bicarbonate (Selective Use): In severe acidosis (pH < 7.1).
  • No Insulin for Lactic Acidosis Alone.

• Toxic Ingestion Treatment:

  • Antidote Administration: If available (fomepizole, ethanol for ethylene glycol/methanol; bicarbonate for salicylate).
  • Enhanced Elimination: Hemodialysis (ethylene glycol, methanol, salicylates).
  • Supportive Care: Fluid resuscitation, electrolyte correction, acidosis management.
  • No Insulin for Toxic Ingestions Alone.

• Diabetic Medication Overdose Treatment:

  • Glucose Administration: Intravenous glucose to correct hypoglycemia.
  • Octreotide (Sulfonylurea Overdose): To inhibit insulin secretion.
  • Monitor for Rebound Hypoglycemia/Hyperglycemia.
  • No Insulin for Overdose-Induced Ketoacidosis.

• Uremia Treatment:

  • Sodium Bicarbonate: Oral or intravenous to correct acidosis.
  • Dialysis: Hemodialysis or peritoneal dialysis for severe uremia.
  • Manage CKD Complications.
  • Adjust Diabetes Medications for Renal Failure.
  • No Insulin for Uremic Acidosis Alone.

• MI Treatment: Standard MI management (reperfusion, medications). Manage stress hyperglycemia if present, but not DKA treatment.

• Pancreatitis Treatment: Supportive care (fluids, pain control, nutritional support). Manage stress hyperglycemia if present, but not DKA treatment.

Conclusion

The differential diagnosis of diabetic ketoacidosis is broad and clinically significant. While DKA is a common and serious complication of diabetes, several other conditions can mimic its presentation. A systematic approach, incorporating detailed history taking, thorough physical examination, and judicious use of laboratory and imaging investigations, is essential for accurate diagnosis. Key differentiating factors include blood glucose levels, serum ketones, lactate levels, anion gap, osmolar gap, clinical context, and specific symptoms and signs associated with each condition.

Accurate differentiation is crucial because the management strategies vary significantly depending on the underlying pathology. Misdiagnosis can lead to inappropriate treatment, delayed care for the actual condition, and potentially adverse patient outcomes. By diligently considering and excluding alternative diagnoses, clinicians can ensure that patients receive the most effective and targeted therapy, ultimately improving outcomes in these complex clinical scenarios. A strong understanding of the differential diagnosis of DKA empowers healthcare professionals to provide optimal care and navigate the complexities of metabolic emergencies effectively.

References

1.Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43. [PMC free article: PMC2699725] [PubMed: 19564476]

2.Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52. [PMC free article: PMC4525004] [PubMed: 26086329]

3.Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017 [PMC free article: PMC5592704] [PubMed: 28924481]

4.Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 28, 2018. [PubMed: 25905369]

5.Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017 Aug 01;7(7):e016587. [PMC free article: PMC5642652] [PubMed: 28765134]

6.Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. Horm Metab Res. 2018 Mar;50(3):209-222. [PubMed: 29523007]

7.Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502. [PubMed: 1765864]

8.Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997 Mar 24;157(6):669-75. [PubMed: 9080921]

9.Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365. [PMC free article: PMC5877353] [PubMed: 29596400]

10.Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care. 2006 Sep;29(9):2018-22. [PubMed: 16936146]

11.Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am. 2004 Jul;88(4):1063-84, xii. [PubMed: 15308390]

12.Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7224-7. [PMC free article: PMC52266] [PubMed: 1651499]

13.Barnes AJ, Bloom SR, Goerge K, Alberti GM, Smythe P, Alford FP, Chisholm DJ. Ketoacidosis in pancreatectomized man. N Engl J Med. 1977 Jun 02;296(22):1250-3. [PubMed: 404553]

14.Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet. 1973 Sep 22;2(7830):635-9. [PubMed: 4125618]

15.Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002 Mar;17(1):63-7. [PubMed: 12040551]

16.Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am. 1995 Jan;79(1):39-52. [PubMed: 7808094]

17.Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci. 1996 May;311(5):225-33. [PubMed: 8615398]

18.Paulson WD, Gadallah MF. Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci. 1993 Nov;306(5):295-300. [PubMed: 8238083]

19.Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53. [PubMed: 11194218]

20.Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med. 1980 Aug;93(2):280-1. [PubMed: 6773457]

21.Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet. 1977 Apr 30;1(8018):929-31. [PubMed: 67388]

22.Vantyghem MC, Haye S, Balduyck M, Hober C, Degand PM, Lefebvre J. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol. 1999 Jun;36(1-2):39-44. [PubMed: 10436251]

23.Weidman SW, Ragland JB, Fisher JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res. 1982 Jan;23(1):171-82. [PubMed: 6799600]

24.Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000567. [PubMed: 23450531]

25.Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011 Jul;29(6):670-4. [PubMed: 20825879]

26.Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, Kruger P, Bellomo R. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. J Crit Care. 2012 Apr;27(2):138-45. [PubMed: 22440386]

27.Van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis–Ringer’s lactate versus normal saline: a randomized controlled trial. QJM. 2012 Apr;105(4):337-43. [PubMed: 22109683]

28.Adrogué HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA. 1989 Oct 20;262(15):2108-13. [PubMed: 2507798]

29.Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, Murphy NP, Bergomi A, Widmer B, Dunger DB. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006 Sep;49(9):2002-9. [PubMed: 16847700]

30.Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): May 9, 2021. [PubMed: 25905280]

31.Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008 Nov;31(11):2081-5. [PMC free article: PMC2571050] [PubMed: 18694978]

32.Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 01;117(5):291-6. [PubMed: 15336577]

33.Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018 Aug;61(2):267-274. [PubMed: 29797212]

34.Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65(4):507-21. [PubMed: 26975543]

35.Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31. [PMC free article: PMC4207202] [PubMed: 25342831]

36.Herpes virus fingerprinting. Lancet. 1979 Feb 03;1(8110):251-2. [PubMed: 84904]

37.Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606. [PMC free article: PMC6535398] [PubMed: 28372715]

38.Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5. [PubMed: 23737516]

39.Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N., Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25;344(4):264-9. [PubMed: 11172153]

40.Osuka A, Matsuoka T, Idoguchi K. Is this the worst outcome of metabolic syndrome? Hypophosphatemia and resulting cardiac arrest during the treatment of diabetic ketoacidosis with hypertriglyceridemia. Intern Med. 2009;48(16):1391-5. [PubMed: 19687585]

41.Regmi A, Konstantinov NK, Agaba EI, Rohrscheib M, Dorin RI, Tzamaloukas AH. Respiratory Failure in the Course of Treatment of Diabetic Ketoacidosis. Clin Diabetes. 2014 Jan;32(1):28-31. [PMC free article: PMC4521429] [PubMed: 26246676]

42.Abbas Q, Arbab S, Haque AU, Humayun KN. Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pak J Med Sci. 2018 Jan-Feb;34(1):106-109. [PMC free article: PMC5856992] [PubMed: 29643888]

43.Kutlu AO, Kara C, Cetinkaya S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr Emerg Care. 2011 Jun;27(6):537-8. [PubMed: 21642790]

44.Konstantinov NK, Rohrscheib M, Agaba EI, Dorin RI, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015 Jul 25;6(8):1009-23. [PMC free article: PMC4515441] [PubMed: 26240698]